

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: tba
Filed: tba
1st Inventor: SHIMIZU, T.
For: Orally Disintegrable Tablets
Atty. Dkt. No. 2522 US2P

Art Unit: 1615
Examiner: S. Tran
Allowed:
Batch:
Paper No.:



Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231
Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449.

Applicants have previously provided copies of references A1-A10 (inclusive) listed on the attached form PTO-1449, in the co-pending parent case, Serial No. 09/355,781, filed August 4, 1999. Copies of references A11-A13 are enclosed for the Examiner's convenience.

This information disclosure statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

For each non-English language reference listed on the attached Form PTO-1449, reference is made to the concise explanation attached thereto.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached Form PTO-1449 be returned in accordance with MPEP §9609.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: October 28, 2001

(847)383-3372
(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA